887 related articles for article (PubMed ID: 28040553)
1. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
Tao T; Jiang X; Chen Y; Song Y
Int J Infect Dis; 2017 Feb; 55():56-71. PubMed ID: 28040553
[TBL] [Abstract][Full Text] [Related]
2. The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis.
Stokes W; Fenton C; Clement F; James M; Ronksley P; Tang KL
Can J Gastroenterol Hepatol; 2017; 2017():6468309. PubMed ID: 28367429
[No Abstract] [Full Text] [Related]
3. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
[TBL] [Abstract][Full Text] [Related]
4. Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis.
Sanai FM; Altraif IH; Alswat K; AlZanbagi A; Babatin MA; AlMousa A; Almutairi NH; Aljawad MS; Alghamdi AS; Aljumah AA; Alalwan AM; Al-Hamoudi WK; Assiri AM; Dahlan Y; Alsahafi A; Alothmani HS; AlSaleemi MS; Mousa WA; Albenmousa A; Awny A; Albiladi H; Abdo AA; AlGhamdi H
J Infect; 2018 Jun; 76(6):536-542. PubMed ID: 29742470
[TBL] [Abstract][Full Text] [Related]
5. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
[TBL] [Abstract][Full Text] [Related]
6. Sofosbuvir-ledipasvir with or without ribavirin for chronic hepatitis C genotype-1 and 6: real-world experience in Vietnam.
Thu Thuy PT; Bunchorntavakul C; Tan Dat H; Palecki J; Reddy KR
Antivir Ther; 2018; 23(5):415-423. PubMed ID: 29303482
[TBL] [Abstract][Full Text] [Related]
7. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.
Tam E; Luetkemeyer AF; Mantry PS; Satapathy SK; Ghali P; Kang M; Haubrich R; Shen X; Ni L; Camus G; Copans A; Rossaro L; Guyer B; Brown RS;
Liver Int; 2018 Jun; 38(6):1010-1021. PubMed ID: 29091342
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials.
Alqahtani SA; Afdhal N; Zeuzem S; Gordon SC; Mangia A; Kwo P; Fried M; Yang JC; Ding X; Pang PS; McHutchison JG; Pound D; Reddy KR; Marcellin P; Kowdley KV; Sulkowski M
Hepatology; 2015 Jul; 62(1):25-30. PubMed ID: 25963890
[TBL] [Abstract][Full Text] [Related]
9. Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment.
Aqel B; Leise M; Vargas HE; Watt KD; Keaveny AP; Zhang N; Zhang N; Pungpapong S
Ann Hepatol; 2018 Aug; 17(5):815-821. PubMed ID: 30145562
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
Moser S; Kozbial K; Laferl H; Schütz A; Reiberger T; Schwabl P; Gutic E; Schwanke C; Schubert R; Luhn J; Lang T; Schleicher M; Steindl-Munda P; Haltmayer H; Ferenci P; Gschwantler M
Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):291-295. PubMed ID: 29120906
[TBL] [Abstract][Full Text] [Related]
11. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.
Reddy KR; Bourlière M; Sulkowski M; Omata M; Zeuzem S; Feld JJ; Lawitz E; Marcellin P; Welzel TM; Hyland R; Ding X; Yang J; Knox S; Pang P; Dvory-Sobol H; Subramanian GM; Symonds W; McHutchison JG; Mangia A; Gane E; Mizokami M; Pol S; Afdhal N
Hepatology; 2015 Jul; 62(1):79-86. PubMed ID: 25846144
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
[TBL] [Abstract][Full Text] [Related]
13. Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: A pairwise meta-analysis.
Ferreira VL; Assis Jarek NA; Tonin FS; Borba HH; Wiens A; Muzzillo DA; Pontarolo R
J Gastroenterol Hepatol; 2017 Apr; 32(4):749-755. PubMed ID: 27785825
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.
Bhattacharya D; Belperio PS; Shahoumian TA; Loomis TP; Goetz MB; Mole LA; Backus LI
Clin Infect Dis; 2017 Jun; 64(12):1711-1720. PubMed ID: 28199525
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir/sofosbuvir.
Modi AA; Nazario HE; Gonzales GR; Gonzalez SA
Aliment Pharmacol Ther; 2018 May; 47(10):1409-1415. PubMed ID: 29569736
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.
Gane EJ; Stedman CA; Hyland RH; Ding X; Svarovskaia E; Subramanian GM; Symonds WT; McHutchison JG; Pang PS
Gastroenterology; 2014 Mar; 146(3):736-743.e1. PubMed ID: 24262278
[TBL] [Abstract][Full Text] [Related]
17. Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels.
Younossi ZM; Elsheikh E; Stepanova M; Gerber L; Nader F; Stamm LM; Brainard DM; McHutchinson JG
J Viral Hepat; 2015 Dec; 22(12):977-82. PubMed ID: 26280786
[TBL] [Abstract][Full Text] [Related]
18. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens.
Wyles D; Pockros P; Morelli G; Younes Z; Svarovskaia E; Yang JC; Pang PS; Zhu Y; McHutchison JG; Flamm S; Lawitz E
Hepatology; 2015 Jun; 61(6):1793-7. PubMed ID: 25846014
[TBL] [Abstract][Full Text] [Related]
19. Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir.
Younossi ZM; Stepanova M; Omata M; Mizokami M; Walters M; Hunt S
Medicine (Baltimore); 2016 Aug; 95(33):e4243. PubMed ID: 27537553
[TBL] [Abstract][Full Text] [Related]
20. Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection.
Liu CH; Su TH; Liu CJ; Hong CM; Yang HC; Tseng TC; Chen PJ; Chen DS; Kao JH
J Gastroenterol Hepatol; 2019 Sep; 34(9):1620-1625. PubMed ID: 30693965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
